CLAIMS

1. Process for modifying the crystal habit of an acicular drug substance comprising suspending said crystalline drug substance in a solvent system having an effect on the crystal habit and subjecting said suspension to a temperature oscillation.

2. Process for recrystallising an acicular drug substance comprising suspending said crystals in a solvent system having an effect on the crystal habit and subjecting said suspension to a temperature oscillation.

3. Process according to claim 1 or 2 wherein the crystal habit is modified in that the mean aspect ratio of the processed crystals is smaller than about 10:1.

4. Process according to any one of claims 1 to 3 wherein the drug substance after temperature oscillation has a bulk density of about above 200 kg/m^3.

5. Process according to any preceding claim wherein the temperature oscillation is in form of a zig-zag curve.

6. A process according to any one of claims 1 to 5 for producing crystals having a mean aspect ratio of the processed crystals smaller than about 10:1 or a bulk density of about 200 kg/m^3.

7. Crystals of an acicular drug substance with an aspect ratio of about 10:1 to 1:1 and/or a bulk density of above about 200 kg/m^3.

8. Crystals according to claim 7 wherein the acicular drug substance is mycophenolic acid or a mycophenolate salt.

9. A pharmaceutical composition, e.g. in the form of tablets, comprising crystals of claim 7 or 8 in association with a pharmaceutically acceptable carrier.

10. Crystals of claim 8 for use as a pharmaceutical.

11. A crystal modification of mycophenolic acid or mycophenolate sodium having one of the following characteristic crystal structures, determined by means of an X-ray single crystal analysis, or having an X-ray powder diffraction pattern as defined below:

a) mycophenolate sodium anhydrate, modification A;

crystal system:	monoclinic
space group:	$P2_1/c$
a:	16.544(4)

b:	4.477(1)
c:	21.993(3)
β:	92.14(1)°
V:	1627.8(6)
Z:	4
cal. Density:	1.397 g/cm^3

b) mycophenolate sodium hydrate;

having an X-ray powder diffraction pattern with characteristic signals substantially the same as those shown in Figure 2;

c) hemisalt of mycophenolate sodium anhydrate;

crystal system:	triclinic
space group:	P-1
a:	11.172(6)
b:	12.020(6)
c:	13.441(2)
α:	73.09(7)°
β:	71.79(6)°
γ:	84.63(6)°
V:	1641(2)
Z:	2

d) mycophenolate sodium methanol solvate;

crystal system:	triclinic
space group:	P-1
a:	7.761
b:	9.588
c:	14.094
α:	109.96°
β:	95.99°
γ:	83.05°
V:	976.3
Z:	2

e) mycophenolate sodium methanol solvate II;

crystal system:	triclinic
space group:	P-1

a:	9.179
b:	10.724
c:	12.098
α:	113.27 °
β:	101.76 °
γ:	104.44 °
V	996.4
Z	2

f) mycophenolate disodium salt, monohydrate;

having an X-ray powder diffraction pattern with characteristic signals substantially the same as those shown in Figure 6;

g) mycophenolate disodium salt, pentahydrate;

crystal system:	monoclinic
space group:	P $2_1/c$,
a:	14.495
b:	17.613
c:	8.401
β:	97.15 °
V	2128
Z	4

h) mycophenolic acid;

crystal system:	triclinic
space group:	P -1
a:	7.342
b:	9.552
c:	11.643
α:	102.70 °
β:	90.89 °
γ:	90.74 °
V	796.3
Z	2

i) mycophenolate sodium hydrate form B;

having an X-ray powder diffraction pattern with characteristic signals substantially the same as those shown in Figure 10;

j) mycophenolate sodium hydrate form C;

having an X-ray powder diffraction pattern with characteristic signals substantially the same as those shown in Figure 12.